BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

Shares of vaccine makers, including Moderna (MRNA), BioNTech (BNTX), Pfizer (PFE), Novavax (NVAX), Vaxcyte (PCVX) and GSK (GSK) moved lower at the end of the trading day following reports that ...

Robert F. Kennedy has been skeptical of vaccines in the past. Names in the vaccine space include Moderna (MRNA), BioNTech (BNTX), Pfizer (PFE), Novavax (NVAX) and GSK (GSK). Published first on TheFly ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million ...

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...